We have a proven track record in practice-changing clinical trials in pancreatic cancer. These have set the standards for the diagnosis (PET PANC study) and adjuvant therapy (ESPAC 4 trial) for patients with pancreatic cancer. Both are part of the NICE Guidelines for the Diagnosis and Management of pancreatic cancer and ESPAC 4 is part of the American Society of Clinical Oncology Guidelines.
Examples of high impact research include:
- the Impact of Human papillomavirus (HPV) on Head and Neck Cancer - UK Evidence Synthesis and Practice Defining Change
- Managing toxicity when treating cancer with next-generation drugs
- Lung Cancer Screening: tackling the commonest cause of cancer death through UKLS catalysing implementation and unique risk modelling to stratify high-risk individuals
- Stratification of primary uveal melanoma (UM) patients into metastatic risk and liver surveillance groups using the integrated Liverpool prognosticator tool
- The development of biomarkers to predict toxicity to immune checkpoint therapies
The department is also home to the Liverpool Cancer Research Institute, led by Professor Andrew Pettitt, which aims to consolidate the existing strengths in biomedical and translational cancer research in Liverpool, grow its capability and accelerate the translation of research into improved patient outcomes.